A systematic study on local failure events post chemoradiotherapy for cervical cancer: understanding the impact of baseline lateral anatomical compartment involvement.
Lucas Gomes Sapienza, Gustavo Guitmann, Christopher G Morris, Paul G Okunieff, Michelle Suzanne Ludwig, Maria José Leite Gomes, Isidore Daniel Benrubi, Karina E Hew
{"title":"A systematic study on local failure events post chemoradiotherapy for cervical cancer: understanding the impact of baseline lateral anatomical compartment involvement.","authors":"Lucas Gomes Sapienza, Gustavo Guitmann, Christopher G Morris, Paul G Okunieff, Michelle Suzanne Ludwig, Maria José Leite Gomes, Isidore Daniel Benrubi, Karina E Hew","doi":"10.1016/j.ijrobp.2025.09.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To dissect the local failure (LF) events, including specific rates by anatomical compartments, after definitive chemoradiotherapy for locally advanced cervical cancer (LACC).</p><p><strong>Methods: </strong>Records of all consecutive women with LACC treated with definitive chemoradiotherapy and image-guided adaptive brachytherapy (IGABT) were reviewed, focusing on the local disease status. No patient received external-beam radiotherapy (EBRT) parametrial boost. Incidence estimations, timing analysis (true persistent disease [TP]) versus new recurrence [NR]), calculations of LF rates by anatomical compartments (at the time of LF detection), and test of association of compartment-specific LF with baseline (at diagnosis) involvement (adjusted odds ratio [aOR]), were performed.</p><p><strong>Results: </strong>Among the 225 patients included (75% FIGO III-IV; 32% IC/IS BT use; median FU 46.2 months), 34 LFs occurred (24 TP; 10 NR), involving 92 anatomical compartments. Isolated LF was the first relapse in 55.9% (19/34), with no events after 3 years, resulting in 6.2% 3-year/5-year overall NR and 16.3% 3-year/5-year overall LF (NR + TP) rates. TP had worse survival compared to NR (2y-OS: 19.1% vs. 72.9%, p=0.04). The most involved compartments were the cervix (79.4%), parametrium (PMT) (61.8%), uterine corpus (33.3%), bladder (14.7%), vagina (11.8%), and mesorectum (2.9%). Recurrence followed the cardinal (CL), uterosacral (USL), and pubocervical (PCL) directions in 58.8%, 35.3%, and 23.5% of cases, respectively. Only two intact PMT at diagnosis developed ipsilateral LF (1.1%, 2/181, CL only), while baseline ipsilateral PMT involvement with hydronephrosis was associated with ipsilateral LF (aOR 22.2, p<0.01, rate: 21.3%, 10/47, involving CL±PCL±USL), but not with contralateral LF (aOR 0.4, p=0.28).</p><p><strong>Conclusion: </strong>In the non-operative setting, the lateral PMT is the second most involved anatomical compartment by LF (>60%) after the cervix (80%). An intact baseline PMT has low frequency (1%) and limited extension (CL only) of ipsilateral failure. In contrast, baseline hydronephrosis is strongly associated with extensive ipsilateral PMT relapse, requiring side-specific treatment intensification.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2025.09.015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To dissect the local failure (LF) events, including specific rates by anatomical compartments, after definitive chemoradiotherapy for locally advanced cervical cancer (LACC).
Methods: Records of all consecutive women with LACC treated with definitive chemoradiotherapy and image-guided adaptive brachytherapy (IGABT) were reviewed, focusing on the local disease status. No patient received external-beam radiotherapy (EBRT) parametrial boost. Incidence estimations, timing analysis (true persistent disease [TP]) versus new recurrence [NR]), calculations of LF rates by anatomical compartments (at the time of LF detection), and test of association of compartment-specific LF with baseline (at diagnosis) involvement (adjusted odds ratio [aOR]), were performed.
Results: Among the 225 patients included (75% FIGO III-IV; 32% IC/IS BT use; median FU 46.2 months), 34 LFs occurred (24 TP; 10 NR), involving 92 anatomical compartments. Isolated LF was the first relapse in 55.9% (19/34), with no events after 3 years, resulting in 6.2% 3-year/5-year overall NR and 16.3% 3-year/5-year overall LF (NR + TP) rates. TP had worse survival compared to NR (2y-OS: 19.1% vs. 72.9%, p=0.04). The most involved compartments were the cervix (79.4%), parametrium (PMT) (61.8%), uterine corpus (33.3%), bladder (14.7%), vagina (11.8%), and mesorectum (2.9%). Recurrence followed the cardinal (CL), uterosacral (USL), and pubocervical (PCL) directions in 58.8%, 35.3%, and 23.5% of cases, respectively. Only two intact PMT at diagnosis developed ipsilateral LF (1.1%, 2/181, CL only), while baseline ipsilateral PMT involvement with hydronephrosis was associated with ipsilateral LF (aOR 22.2, p<0.01, rate: 21.3%, 10/47, involving CL±PCL±USL), but not with contralateral LF (aOR 0.4, p=0.28).
Conclusion: In the non-operative setting, the lateral PMT is the second most involved anatomical compartment by LF (>60%) after the cervix (80%). An intact baseline PMT has low frequency (1%) and limited extension (CL only) of ipsilateral failure. In contrast, baseline hydronephrosis is strongly associated with extensive ipsilateral PMT relapse, requiring side-specific treatment intensification.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.